Treatment of Congenital Osteopetrosis with High-Dose Calcitriol

Lyndon Key, David Carnes, Sessions Cole, Marijke Holtrop, Zvi Bar-Shavit, Fred Shapiro, Robert Arceci, James Steinberg, Caren Gundberg, Arnold Kahn, Steven Teitelbaum, Constantine Anast

Research output: Contribution to journalArticlepeer-review

141 Scopus citations


We administered high doses of calcitriol (up to 32 μg per day) to an infant with malignant osteopetrosis, in an attempt to stimulate bone resorption. The patient was placed on a low-calcium diet to prevent hypercalcemia. Measures of bone turnover increased during calcitriol therapy; hydroxyproline excretion rose from 140 to 1358 μg per milligram of creatinine per 24 hours, with parallel increases in the ratio of calcium to creatinine in the urine, urinary gamma-carboxyglutamic acid, serum osteocalcin, and serum alkaline phosphatase. A pretreatment bone-biopsy specimen contained no osteoclasts with ruffled borders, a feature of active osteoclasts. After 11 days of calcitriol, ruffled borders were noted. After three months, numerous osteoclasts with ruffled borders and associated bony disruption were evident. Before therapy, the patient's monocytes were incapable of in vitro bone resorption, but after calcitriol, their resorptive capacity was increased to 3.3 times control levels. These data demonstrate that calcitriol increased bone mineral and matrix turnover in our patient. However, during the three months of calcitriol therapy there was only slight clinical improvement in her severe disease. Early and sustained treatment with calcitriol may be useful in osteopetrosis. (N Engl J Med 1984; 310:409–15.).

Original languageEnglish (US)
Pages (from-to)409-415
Number of pages7
JournalNew England Journal of Medicine
Issue number7
StatePublished - Feb 16 1984

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Treatment of Congenital Osteopetrosis with High-Dose Calcitriol'. Together they form a unique fingerprint.

Cite this